Chicago Partners Investment Group
TSHA icon

Chicago Partners Investment Group’s Taysha Gene Therapies TSHA Stock Holding History

Chicago Partners Investment Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
222,347
+51,596
+30% +$305K 0.03% 536
2026
Q1 		$1.15M Buy
170,751
+4,210
+3% +$19.6K 0.03% 490
2025
Q4 		$776K Buy
166,541
+2,504
+2% +$12.2K 0.02% 550
2025
Q3 		$819K Buy
164,037
+271
+0.2% +$767 0.02% 487
2025
Q2 		$441K Buy
163,766
+47,201
+40% +$103K 0.01% 652
2025
Q1 		$221K Buy
116,565
+521
+0.4% +$871 0.01% 825
2024
Q4 		$224K Sell
116,044
-2,131
-2% -$4.42K 0.01% 776
2024
Q3 		$233K Buy
118,175
+1,270
+1% +$2.79K 0.01% 706
2024
Q2 		$263K Sell
116,905
-8,379
-7% -$24.4K 0.01% 630
2024
Q1 		$317K Sell
125,284
-9,567
-7% -$19.9K 0.01% 558
2023
Q4 		$198K Buy
134,851
+23,740
+21% +$47.3K 0.01% 663
2023
Q3 		$242K Buy
+111,111
New +$208K 0.01% 559

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Chicago Partners Investment Group's TSHA Position: Q2 2026 in Review

Chicago Partners Investment Group increased its Taysha Gene Therapies (TSHA) stake by 30% in Q2 2026, buying an estimated $305K and bringing the position to 222,347 shares worth $1.3M. The position accounts for 0.03% of the portfolio, ranked #536.

Chicago Partners Investment Group first reported a position in TSHA in Q3 2023 and has held it in 12 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Chicago Partners Investment Group held 222,347 shares of Taysha Gene Therapies worth $1.3M as of Q2 2026.
  • Chicago Partners Investment Group bought 51,596 Taysha Gene Therapies shares in Q2 2026, an estimated $305K.
  • Taysha Gene Therapies made up 0.03% of Chicago Partners Investment Group's portfolio in Q2 2026, its #536 holding.
  • Chicago Partners Investment Group first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 12 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.